New drug batoclimab aims to reduce eye bulging in thyroid eye disease

NCT ID NCT05524571

Completed Disease control Sponsor: Immunovant Sciences GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested whether batoclimab, an injected antibody, can reduce eye bulging (proptosis) in people with active, moderate-to-severe thyroid eye disease. 86 participants received weekly injections of batoclimab or a placebo for 24 weeks. The main goal was to see how many people had at least a 2-millimeter reduction in eye protrusion without worsening in the other eye.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: batoclimab (a monoclonal antibody injection)
What this could lead to: If successful, batoclimab could offer a new treatment option to reduce eye bulging and inflammation in people with active thyroid eye disease.
What could go wrong: This is a relatively small Phase 3 trial (86 participants), and results may not apply to all patients. The drug may cause side effects or fail to show meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

Site Number - 1512

Winston-Salem, North Carolina, 27157, United States
Site Number - 1513

Rochester, Minnesota, 55905, United States
Site Number - 1518

Milwaukee, Wisconsin, 53226, United States
Site Number - 1521

Seattle, Washington, 98104, United States
Site Number - 1524

McAllen, Texas, 78503, United States
Site Number - 1525

Portland, Oregon, 97239, United States
Site Number - 1526

Livonia, Michigan, 48152, United States
Site Number - 3605

Barcelona, 08035, Spain
Site Number - 4672

Brussels, 1070, Belgium
Site Number - 4673

Brussels, 1200, Belgium
Site Number - 4674

Liège, 4000, Belgium
Site Number - 4950

Ankara, 6100, Turkey (Türkiye)
Site Number - 4951

Istanbul, 34010, Turkey (Türkiye)
Site Number - 4952

Adana, 13860, Turkey (Türkiye)
Site Number - 6603

Mainz, Rhineland-Palatinate, 55131, Germany
Site Number - 7550

Budapest, 1133, Hungary
Site Number - 7551

Pécs, 7621, Hungary
Site Number - 7552

Pécs, 7623, Hungary
Site Number - 7565

Sydney, 2000, Australia
Site Number - 7570

Christchurch, 8013, New Zealand
Site Number - 7572

Hamilton, 3204, New Zealand
Site Number - 9200

Bratislava, 82606, Slovakia
Site Number - 9201

Bratislava, 85107, Slovakia
Site Number - 9202

Trenčín, 91101, Slovakia
Site Number - 9203

Bratislava, 81108, Slovakia
Site Number - 9302

Ventspils, LV-3601, Latvia
Site Number -1510

Sarasota, Florida, 34239, United States
Site Number -1511

Morgantown, West Virginia, 26506, United States
Site Number -1514

Torrance, California, 90502, United States
Site Number -1515

Bellaire, Texas, 77401, United States
Site Number -1516

Louisville, Kentucky, 40202, United States
Site Number -1517

San Francisco, California, 94143, United States
Site Number -1519

San Antonio, Texas, 78215, United States
Site Number -1520

Pasadena, California, 91107, United States
Site Number -1990

San Juan, 00921, Puerto Rico
Site Number -3600

Santiago de Compostela, 15706, Spain
Site Number -3601

Madrid, 28007, Spain
Site Number -3602

Barcelona, 08006, Spain
Site Number -3603

Valencia, 46026, Spain
Site Number -3604

Madrid, 28034, Spain
Site Number -3606

Seville, 41009, Spain
Site Number -4670

Ghent, B-9000, Belgium
Site Number -4671

Bruges, 8000, Belgium
Site Number -9300

Riga, LV-1006, Latvia
Site Number -9301

Ogre, LV-5001, Latvia

More trials for these conditions

Other studies related to the condition(s) this trial covers.